Associations - PIK3CA E545K

PIK3CA E545K PIK3CA E545K	Hepatocellular Cancer HCC	PIK3CA E545K PIK3CA E545K	Hepatocellular Cancer HCC	alpelisib Sensitive: D – Preclinical Cell Death Dis - 1 week	alpelisib Sensitive: D – Preclinical Cell Death Dis - 1 week
PIK3CA E545K PIK3CA E545K	Colorectal Cancer CRC	PIK3CA E545K PIK3CA E545K	Colorectal Cancer CRC	cetuximab Resistant: C3 – Early Trials	cetuximab Resistant: C3 – Early Trials
PIK3CA E545K PIK3CA E545K	Non Small Cell Lung Cancer NSCLC	PIK3CA E545K PIK3CA E545K	Non Small Cell Lung Cancer NSCLC	osimertinib Resistant: C3 – Early Trials	osimertinib Resistant: C3 – Early Trials
PIK3CA E545K PIK3CA E545K	Ovarian Cancer Ovarian Cancer	PIK3CA E545K PIK3CA E545K	Ovarian Cancer Ovarian Cancer	TAS-117 Sensitive: C3 – Early Trials	TAS-117 Sensitive: C3 – Early Trials
PIK3CA E545K PIK3CA E545K	Breast Cancer Breast Cancer	PIK3CA E545K PIK3CA E545K	Breast Cancer Breast Cancer	olaparib + durvalumab + AZD5363 Sensitive: C3 – Early Trials	olaparib + durvalumab + AZD5363 Sensitive: C3 – Early Trials
PIK3CA E545K PIK3CA E545K	Gastric Cancer Gastric Cancer	PIK3CA E545K PIK3CA E545K	Gastric Cancer Gastric Cancer	CYH33 Sensitive: C4 – Case Studies	CYH33 Sensitive: C4 – Case Studies
PIK3CA E545K PIK3CA E545K	Breast Cancer Breast Cancer	PIK3CA E545K PIK3CA E545K	Breast Cancer Breast Cancer	CYH33 Sensitive: C4 – Case Studies	CYH33 Sensitive: C4 – Case Studies
PIK3CA E545K PIK3CA E545K	Ovarian Cancer Ovarian Cancer	PIK3CA E545K PIK3CA E545K	Ovarian Cancer Ovarian Cancer	CYH33 Sensitive: C4 – Case Studies	CYH33 Sensitive: C4 – Case Studies
PIK3CA E545K PIK3CA E545K	Breast Cancer Breast Cancer	PIK3CA E545K PIK3CA E545K	Breast Cancer Breast Cancer	GDC-0941 Sensitive: D – Preclinical	GDC-0941 Sensitive: D – Preclinical
PIK3CA E545K PIK3CA E545K	Breast Cancer Breast Cancer	PIK3CA E545K PIK3CA E545K	Breast Cancer Breast Cancer	MK-2206 Sensitive: D – Preclinical	MK-2206 Sensitive: D – Preclinical
PIK3CA E545K PIK3CA E545K	Breast Cancer Breast Cancer	PIK3CA E545K PIK3CA E545K	Breast Cancer Breast Cancer	lapatinib Sensitive: D – Preclinical	lapatinib Sensitive: D – Preclinical
PIK3CA E545K PIK3CA E545K	HER2 Positive Breast Cancer HER2 Positive Breast Cancer	PIK3CA E545K PIK3CA E545K	HER2 Positive Breast Cancer HER2 Positive Breast Cancer	ado-trastuzumab emtansine Sensitive: D – Preclinical	ado-trastuzumab emtansine Sensitive: D – Preclinical
PIK3CA E545K PIK3CA E545K	Breast Cancer Breast Cancer	PIK3CA E545K PIK3CA E545K	Breast Cancer Breast Cancer	trastuzumab + lapatinib Resistant: D – Preclinical	trastuzumab + lapatinib Resistant: D – Preclinical
PIK3CA E545K PIK3CA E545K	Thyroid Gland Papillary Carcinoma Thyroid Gland Papillary Carcinoma	PIK3CA E545K PIK3CA E545K	Thyroid Gland Papillary Carcinoma Thyroid Gland Papillary Carcinoma	MK-2206 Sensitive: D – Preclinical	MK-2206 Sensitive: D – Preclinical
PIK3CA E545K PIK3CA E545K	Squamous Cell Carcinoma of Head and Neck SCCHN	PIK3CA E545K PIK3CA E545K	Squamous Cell Carcinoma of Head and Neck SCCHN	RTB101 Sensitive: D – Preclinical	RTB101 Sensitive: D – Preclinical
PIK3CA E545K PIK3CA E545K	Squamous Cell Carcinoma of Head and Neck SCCHN	PIK3CA E545K PIK3CA E545K	Squamous Cell Carcinoma of Head and Neck SCCHN	BMS-722782 Resistant: D – Preclinical	BMS-722782 Resistant: D – Preclinical
PIK3CA E545K PIK3CA E545K	Squamous Cell Carcinoma of Head and Neck SCCHN	PIK3CA E545K PIK3CA E545K	Squamous Cell Carcinoma of Head and Neck SCCHN	trametinib Resistant: D – Preclinical	trametinib Resistant: D – Preclinical
PIK3CA E545K PIK3CA E545K	Squamous Cell Carcinoma of Head and Neck SCCHN	PIK3CA E545K PIK3CA E545K	Squamous Cell Carcinoma of Head and Neck SCCHN	GDC-0941 Resistant: D – Preclinical	GDC-0941 Resistant: D – Preclinical
PIK3CA E545K PIK3CA E545K	Squamous Cell Carcinoma of Head and Neck SCCHN	PIK3CA E545K PIK3CA E545K	Squamous Cell Carcinoma of Head and Neck SCCHN	rigosertib Sensitive: D – Preclinical	rigosertib Sensitive: D – Preclinical
PIK3CA E545K PIK3CA E545K	Squamous Cell Carcinoma of Head and Neck SCCHN	PIK3CA E545K PIK3CA E545K	Squamous Cell Carcinoma of Head and Neck SCCHN	GDC-0032 Sensitive: D – Preclinical	GDC-0032 Sensitive: D – Preclinical
PIK3CA E545K PIK3CA E545K	Melanoma Melanoma	PIK3CA E545K PIK3CA E545K	Melanoma Melanoma	vemurafenib Resistant: D – Preclinical	vemurafenib Resistant: D – Preclinical